January was a big month for pharmaceutical stocks, with Merck (MRK -0.68%), Eli Lilly (LLY 1.42%), and Novo Nordisk (NVO -0.23%) all climbing 11%, according to data provided by S&P Global Market Intelligence. Investors are excited about the potential market for weight-loss drugs, and that attention has driven momentum for some of the larger pharma stocks.There wasn't much major news from these companies in January, but there was enough positive buzz to build on the existing momentum ahead of quarterly-earni ...

Eli Lilly (LLY 2.89%) had a very good year in 2023. Revenue jumped 20% and its stock skyrocketed 59%. The company also claimed the mantle as the world's largest drugmaker by market cap. Will the momentum continue going forward? Probably. However, it won't be as easy as some might think. Here are four reasons why 2024 could be Eli Lilly's worst year for the rest of this decade.1. Trulicity supply shortageType 2 diabetes drug Trulicity ranked as Lilly's top-selling drug last year, raking in sales of more than ...

ToplineMinnesota Attorney General Keith Ellison announced Wednesday that pharmaceutical giant Eli Lilly will donate insulin to clinics around the state for the next five years—and keep a $35 price cap for all patients in the state—to settle allegations that it “deceptively priced” its insulin products, brought by the state in a 2018 lawsuit.The terms of the five-year settlement begin immediately, with Eli Lilly agreeing to donate insulin ... [+] to 15 clinics in the state.Copyright 2023 The Associated Press ...

Eli Lilly and Co (NYSE:LLY) Q4 2024 Earnings Conference Call February 6, 2024 10:00 AM ET Company Participants Joe Fletcher - SVP, IR David Ricks - Chairman, CEO & President Anat Ashkenazi - EVP & CFO Daniel Skovronsky - Chief Scientific Officer and President of Lilly Immunology Ilya Yuffa - EVP of Eli Lilly and Company and President of Lilly International Patrik Jonsson - President of Lilly Diabetes and obesity and Lilly U.S.A Conference Call Participants Terence Flynn - Morgan Stanley Christopher Schott - ...

The trillion-dollar market valuation club is currently dominated by the tech sector. Saudi Aramco is the sole exception. The other six members are all part of the Nasdaq’s Magnificent Seven. But if people keep getting prescriptions for popular weight loss drugs Mounjaro and Ozempic, it may not be long before the two Big Pharma firms that make those injectable medications wind up worth at least a trillion dollars as well.Eli Lilly (NYSE:LLY), the company behind Mounjaro and Zepbound, is now worth nearly $670 ...

Good afternoon! All eyes are on Novo Nordisk and Eli Lilly again as Wall Street looks for signs that they can address one of the biggest hurdles they faced last year. Neither company has enough supply to meet the insatiable demand for their weight loss and diabetes drugs. One month into 2024, the two drugmakers still haven't fully resolved those supply issues. They don't expect to soon. Still, Eli Lilly and Novo Nordisk appear to be making some encouraging progress.Eli Lilly achieved its goal of doubling it ...

| --- | --- | --- | |-----------------------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | Eli Lilly and Company | | | | | | | | | | | | Q4 2023 Earnings Call | | | | February 6, 2024 | | | Safe Harbor Provision 2 This presentation contains forward-looking statements that are based on management's current expectations, but actual results may differ materially due to various factors. The company's results may be affected by factors including, but not limited to, the risks and uncertainti ...

Eli Lilly (LLY) reported $9.35 billion in revenue for the quarter ended December 2023, representing a year-over-year increase of 28.1%. EPS of $2.49 for the same period compares to $2.09 a year ago.The reported revenue represents a surprise of +5.53% over the Zacks Consensus Estimate of $8.86 billion. With the consensus EPS estimate being $2.47, the EPS surprise was +0.81%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine t ...

An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023.Eli Lilly on Tuesday said its highly popular drug used for weight loss and diabetes showed promise as a treatment for fatty liver disease in a mid-stage trial. The initial study results add to a long list of potential health benefits of the treatment, known as tirzepatide, besides helping patients shed significant pounds and regulate blood sugar under the drug's brand names, Zepbound and Mounja ...

Eli Lilly and Company (LLY) reported fourth-quarter 2023 adjusted earnings per share (“EPS”) of $2.49, which beat the Zacks Consensus Estimate of $2.46 per share. Earnings rose 19% year over year.Revenues of $9.35 billion beat the Zacks Consensus Estimate of $8.86 billion. Sales rose 28% year over year, driven by exceptionally strong demand for Lilly’s FDA-approved tirzepatide medicines, diabetes drug Mounjaro and newly launched weight loss medicine, Zepbound.Quarter in DetailIn the reported quarter, net re ...